THE Health Department has announced the addition of secukinumab and ixekizumab into its post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis.
Sponsors of the medicines recently added to the group will be invited to provide a submission to the review, while stakeholders who have previously provided input to the now closed consultation will also be invited to update their submissions if required - pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Mar 17